Esperion Therapeutics (ESPR) released Loss for fourth quarter of -$21.32 million
The company's bottom line came in at -$21.32 million, or -$0.11 per share. This compares with -$56.34 million, or -$0.50 per share, last year.
The company's revenue for the period rose 114.3% to $69.11 million from $32.25 million last year.
Esperion Therapeutics earnings at a glance (GAAP) :
-Earnings: -$21.32 Mln. vs. -$56.34 Mln. last year.
-EPS: -$0.11 vs. -$0.50 last year.
-Revenue: $69.11 Mln vs. $32.25 Mln last year.
For comments and feedback: editorial@rttnews.com